18-FDG PET/CT assessment of basal cell carcinoma with vismodegib

Curtis A Thacker, Glen J Weiss, Raoul Tibes, Lisa Blaydorn, Molly Downhour, Erica White, Jason Baldwin, Daniel D Hoff, Ronald L Korn, Curtis A Thacker, Glen J Weiss, Raoul Tibes, Lisa Blaydorn, Molly Downhour, Erica White, Jason Baldwin, Daniel D Hoff, Ronald L Korn

Abstract

The use of 18-fluorodeoxyglucose (FDG) positron emission tomography with computed tomography (PET/CT) in subjects with advanced basal cell carcinoma (BCC) has not been fully explored due to the rarity of disease presentation. This study evaluated PET/CTs from subjects with advanced BCC participating in a phase I dose-escalation clinical trial of vismodegib. Fourteen subjects with BCC were imaged with 18-FDG PET/CT for lesion identification and response categorizing (European Organisation for Research and Treatment for Cancer [EORTC] and PET response criteria in solid tumors [PERCIST] 1.0). Several parameters including metabolic activity of target lesions, site of disease presentation and spread, treatment response, and prognostic significance of metabolic activity following therapy were evaluated. All subjects exhibited at least one hypermetabolic lesion. Most subjects had only four organ systems involved at study enrollment: skin-muscle (93%), lung (57%), lymph nodes (29%), and bone (21%). SUVmax measured across all lesions decreased (median 33%, SD ± 45%) following therapy with metabolic activity normalizing or disappearing in 42% of lesions. No significant difference was observed between EORTC and PERCIST 1.0. Subjects that demonstrated at least a 33% reduction in SUVmax from baseline had a significantly longer progression-free survival (PFS) (median 17 months, 95% confidence interval [CI] ±4 months vs. 9 months, 95% CI ±5 months, P = 0.038) and overall survival (OS) (median 24 months, 95% CI ±4 months vs. 17 months, 95% CI ±13 months, P = 0.019). BCC lesions are hypermetabolic on 18-FDG PET/CT. A decrease in SUVmax was associated with improved PFS and OS. These results further support the incorporation of 18-FDG PET/CT scans in advanced BCC management.

Trial registration: ClinicalTrials.gov NCT00607724.

Keywords: Basal cell carcinoma; PET/CT; imaging; vismodegib.

Figures

Figure 1
Figure 1
Representative images from 18-FDG PET/CT scans. Panels A–D represent baseline and follow-up 18F-FDG PET/CT scans in two separate subjects with soft tissue, bone, and muscle involvement (panels A and B; SUVmax 5.6 vs. 2.8 baseline vs. follow-up, respectively) and lung involvement (panels C and D; SUVmax 12.6 vs. 0.2 at baseline vs. follow-up, respectively). Panels E–H are sample images demonstrating typical locations of BCC metastasis on 18-FDG PET/CT in the skull base (E), lymph nodes (F), lungs, bone, and pleural space (G and H). Panels I–J show the value of baseline axial 18-FDG PET/CT image and three-dimensional CT volume rendering depicting the extent of superficial and deep tissue lesion involvement of a hypermetabolic lesion (SUVmax 21.1; panels I and K) of the inferior left orbit, left cheek, nasal tissues, and maxillary tissue. After therapy, the axial 18-FDG PET/CT fusion image and three-dimensional CT volume rendering exhibited significant reduction in metabolic activity (SUVmax

Figure 2

Progression-free survival ( P =…

Figure 2

Progression-free survival ( P = 0.038) (A) and overall survival ( P =…

Figure 2
Progression-free survival (P = 0.038) (A) and overall survival (P = 0.019) (B); Kaplan–Meier (censored) curves demonstrating significant differences in days between subjects with at least 33% reduction (solid line) in SUVmax compared to those exhibiting less than 33% reduction in SUVmax (broken line).
Figure 2
Figure 2
Progression-free survival (P = 0.038) (A) and overall survival (P = 0.019) (B); Kaplan–Meier (censored) curves demonstrating significant differences in days between subjects with at least 33% reduction (solid line) in SUVmax compared to those exhibiting less than 33% reduction in SUVmax (broken line).

References

    1. Christenson LJ, Borrowman TA, Vachon CM, Tollefson NM, Otley CC, Weaver AL, et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA. 2005;294:681–690.
    1. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br. J. Dermatol. 2002;146:1–6.
    1. Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N. Engl. J. Med. 2005;353:2262–2269.
    1. Wadhera A, Fazio M, Bricca G, Stanton O. Metastatic basal cell carcinoma: a case report and literature review. How accurate is our incidence data? Dermatol. Online J. 2006;12:7.
    1. Hahn H, Wicking C, Zaphiropoulous PG, Gailani MR, Shanley S, Chidambaram A, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85:841–851.
    1. Xie J, Murone M, Luoh SM, Ryan A, Gu Q, Zhang C, et al. Activating smoothened mutations in sporadic basal cell carcinoma. Nature. 1998;391:90–92.
    1. Weiss GJ, Von Hoff DD. Hunting the hedgehog pathway. Clin. Pharmacol. Ther. 2010;87:743–747.
    1. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 2009;361:1164–1172.
    1. Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, Postmus H, van Tinteren PE, et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J. Clin. Oncol. 2005;23:8362.
    1. Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D, et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J. Clin. Oncol. 2000;18:1689–1695.
    1. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ, et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J. Nucl. Med. 2002;43:1018–1027.
    1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000;92:205–216.
    1. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 2009;50:122S–150S.
    1. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J. Clin. Oncol. 2001;19:3058–3065.
    1. Fosko SW, Hu W, Cook TF, Lowe VJ. Positron emission tomography for basal cell carcinoma of the head and neck. Arch. Dermatol. 2003;139:1141–1146.
    1. Barksdale SK, O'Connor N, Barnhill R. Prognostic factors for cutaneous squamous cell and basal cell carcinoma. Determinants of risk of recurrence, metastasis, and development of subsequent skin cancers. Surg. Oncol. Clin. N. Am. 1997;6:625–638.
    1. Domarus H, Stevens P. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in literature. J. Am. Acad. Dermatol. 1984;10:1043–1060.
    1. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J. Clin. Oncol. 2007;25:3746–3752.
    1. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, et al. Gemcitabine plus nab-Paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J. Clin. Oncol. 2011;29:4548–4554.
    1. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N. Engl. J. Med. 2012;366:2171–2179.
    1. National Institute of Health. Bethesda, MD: 2012. Available at (accessed 18 August 2012)

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere